“…In conclusion, BChE activity can be regarded as a biomarker in PD, especially in PD-related dementia. The same function has also been reported in other disorders, including Alzheimer's disease [ 11 ], vascular dementia [ 25 ], ischemic stroke [ 26 ], traumatic brain injury [ 7 ], postoperative delirium [ 27 ], severe trauma [ 28 ], septic shock [ 29 ], burn injuries [ 30 ], adverse cardiac events [ 16 ], hepatic disease [ 17 ], diabetes [ 31 ], and hyperlipidemia [ 32 ]. A former study on AChE levels in PD patients suggested that polymorphisms in ACHE genes fail to initiate ACHE expression, resulting in an impaired Ach/DA balance and subsequent vulnerability of dopaminergic neurons and PD development [ 9 ].…”